Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cipla
QuintilesIMS
Baxter
McKesson
Chinese Patent Office
Accenture
Farmers Insurance
Johnson and Johnson

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,031,125

« Back to Dashboard

Title: 3-Sulfonate ester of 2,3-dihydroxypropylamine
Abstract:Preparation of an optically active alkamine in the sinister configuration, or a derivative of said alkamine, which is reacted with an 3-X-4-chloro(or RO- where R is hydrogen or an alkali metal)-1,2,5-thiadiazole to prepare S-3-X-4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazole beta adrenergic blocking agents. Novel 3-morpholino-4-chloro(or RO-)-1,2,5-thiadiazoles and their preparation also are described.
Inventor(s): Weinstock; Leonard M. (Belle Mead, NJ), Tull; Roger J. (Metuchen, NJ), Mulvey; Dennis M. (Milford, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Filing Date:Oct 24, 1975
Application Number:05/625,616
Claims:1. An optically active glycolamine in the sinister configuration substantially completely free from the rectus isomer having the structure ##STR7## wherein R.sup.3 is lower alkylsulfonyl, benzenesulfonyl or mono- to tri-substituted benzenesulfonyl wherein the substituents are similar or dissimilar and are lower alkyl, lower alkoxy, halo, amino or nitro; Am is the amino group or monoloweralkyl-substituted amino.

2. An optically active glycolamine in the sinister configuration substantially completely free from the rectus isomer having the structure ##STR8## wherein R.sup.3 is lower alkylsulfonyl, benzenesulfonyl or mono- to tri-substituted benzenesulfonyl wherein the substituents are similar or dissimilar and are lower alkyl, lower alkoxy, halo, amino or nitro; and Y is a straight or branched chain lower alkyl.

3. ##STR9## substantially completely free from contamination with its rectus isomer wherein R.sup. 3 is lower alkylsulfonyl, benzenesulfonyl or mono- to tri-substituted benzenesulfonyl wherein the substituents are similar or dissimilar and are lower alkyl, lower alkoxy, halo, amino or nitro; and Y is branched chain lower alkyl.

4. S(-)-1-toluenesulfonyloxy-2-hydroxy-3-tertbutylaminopropane substantially completely free from contamination with its rectus isomer.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
US Department of Justice
Fuji
UBS
Queensland Health
Dow
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.